The clinical puzzle began with a routine coagulation workup. The patient’s activated partial thromboplastin time, or APTT, one of the most commonly ordered tests in hospital laboratories, was found to be significantly prolonged. APTT measures the efficiency of the intrinsic pathway of coagulation, the branch of the clotting system that depends on a chain of protein factors circulating in plasma. When one link in that chain is missing or defective, the test tube reaction slows dramatically and the reported time lengthens. In most circumstances, a markedly prolonged APTT signals an elevated risk of bleeding and triggers a cascade of further testing, transfusion planning, and, in surgical contexts, potential postponement of procedures. For this patient, however, the laboratory abnormality stood in stark contradiction to the clinical picture, a phenomenon hematologists call genotype-phenotype dissociation.

The Chinese team, led by Fengjiao Wang and corresponding author Lihong Yang of the Department of Laboratory Medicine, pursued the discrepancy systematically. Mixing studies and factor assays pointed away from the classic deficiency states and toward a deficit of high-molecular-weight kininogen, a large plasma protein known as HMWK that serves as a cofactor in the intrinsic pathway. HMWK does not itself possess procoagulant enzymatic activity; instead, it acts as a molecular scaffold, binding to negatively charged surfaces and positioning factor XI and prekallikrein for activation by factor XIIa. Without HMWK, this assembly fails, and the in vitro clotting reaction measured by APTT grinds to a halt. Crucially, however, the in vivo relevance of this pathway to hemostasis has long been questioned, and individuals with complete HMWK deficiency characteristically bleed no more than healthy people, because the extrinsic and tissue factor pathways compensate for the intrinsic defect in real life.

Genetic sequencing provided the definitive answer. The analysis identified a novel homozygous deletion, designated c.628_629delAA, located in exon 5 of the KNG1 gene, which encodes the kininogen precursor protein. The deletion of two adenine bases is a classic frameshift mutation: it shifts the reading frame of the genetic code from that point onward, scrambling every downstream codon. In this case, the frameshift generates the amino acid substitution p.Asn210Phe at the new reading position and then, just fourteen codons later, introduces a premature termination codon, producing the notation fs*15. The result is a truncated protein that lacks the functional domains essential for HMWK’s role in the contact phase of coagulation. Applying the standards of the American College of Medical Genetics and Genomics, the team classified the variant as pathogenic, given its nature as a loss-of-function frameshift in a gene whose biallelic loss produces the observed biochemical phenotype.

The inheritance pattern followed classical autosomal recessive genetics. Because the patient inherited two copies of the mutant allele, one from each parent, essentially no functional HMWK was produced, and APTT values soared. Family screening revealed that heterozygous relatives carrying a single mutant copy had mildly reduced HMWK activity, yet their APTT values remained entirely within the normal range. This dose-effect relationship demonstrates that a single functional KNG1 allele produces enough kininogen to sustain a normal laboratory coagulation profile, while two defective alleles are required to unmask the abnormality. The finding has direct implications for genetic counseling: carriers are asymptomatic and undetectable by routine coagulation testing, so only molecular analysis can identify them, and only molecular analysis of both parents can predict recurrence risk in future pregnancies.

The rarity of the condition adds to its scientific value. Hereditary HMWK deficiency, historically known as Fitzgerald trait after the first described patient, has been reported in only a small number of families worldwide, and each new case contributes to a mutational catalog that remains strikingly short. The novel c.628_629delAA deletion identified in this Chinese patient expands that catalog and illustrates the kind of variant most likely to cause the condition: loss-of-function mutations that truncate the protein before its critical binding domains. Previous reported cases have involved diverse mutations scattered across the gene, consistent with the expectation that many different disruptions of KNG1 can produce the same laboratory phenotype. The Wenzhou case also highlights that the condition may be substantially underdiagnosed, since many affected individuals, being clinically healthy, may never come to medical attention unless an APTT happens to be checked before surgery or during an unrelated evaluation.

The clinical stakes of correct diagnosis are considerable. A prolonged APTT in a preoperative patient conventionally prompts either cancellation of surgery, empirical correction attempts with fresh frozen plasma, or extensive hematologic investigation for hemophilia, von Willebrand disease, lupus anticoagulants, or acquired inhibitors. Each of these pathways carries cost, delay, and in the case of plasma transfusion, genuine risk of transfusion reactions or alloimmunization. Recognizing that isolated APTT prolongation with normal prothrombin time, normal bleeding history, and reduced HMWK activity indicates a benign entity allows clinicians to proceed with appropriate reassurance. The authors of the report emphasize that systematic genetic screening of both patients and their family members is clinically important, not merely for scientific completeness, but because definitive molecular characterization resolves diagnostic uncertainty that biochemical testing alone cannot.

The report also contributes to a broader biological conversation about why the contact pathway exists at all. Decades of research have shown that individuals deficient in factor XII or HMWK do not bleed abnormally, even though their APTT values can be extraordinarily prolonged. This paradox has reshaped thinking in thrombosis research: if the intrinsic pathway is dispensable for preventing bleeding, it may nevertheless be essential for pathological clot formation, and inhibiting contact-phase proteins has become an attractive antithrombotic strategy that could theoretically prevent clots without increasing bleeding risk. Rare patients like this one serve as natural experiments that validate such approaches, demonstrating at the level of human physiology that a lifetime of absent HMWK activity is compatible with normal hemostasis. Epidemiological observations have even suggested that severe HMWK deficiency may protect against venous thromboembolism, adding an intriguing twist to the story of a mutation that leaves its carrier laboratory-abnormal but clinically well.

From a laboratory medicine perspective, the case underscores the importance of a disciplined diagnostic algorithm for unexplained APTT prolongation. The standard sequence begins with mixing studies, which distinguish factor deficiencies, where pooled normal plasma corrects the prolongation, from inhibitors, where it does not. Correction then leads to sequential factor assays through the intrinsic pathway: factors VIII, IX, XI, and XII, followed by the less commonly tested contact proteins, prekallikrein and HMWK. Because HMWK deficiency is so rare, it is often the last possibility considered, and many laboratories lack routine access to kininogen activity assays. The Wenzhou group’s workflow, moving from coagulation phenotyping to targeted sequencing of the KNG1 gene, offers a template other centers can follow. The measurement of profoundly reduced HMWK activity in the proband, alongside mildly reduced activity in heterozygous relatives, illustrates how genotype and biochemical phenotype track together in this condition with unusual precision.

The report, which was peer reviewed and published with a permanent DOI as an early-access article subject to final editorial production, was approved by the ethics committee of The First Affiliated Hospital of Wenzhou Medical University, and the authors declared no competing interests. The work was supported by the Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province and by municipal science and technology funds from Wenzhou. Beyond its immediate value to hematologists and laboratory physicians, the case stands as a vivid reminder that the genome continues to hold explanations for laboratory curiosities that have puzzled clinicians for generations, and that the tool most likely to resolve them, systematic sequencing of patients and their families, has now become fast and affordable enough to be applied whenever a blood test and a bedside picture refuse to agree. For the patient at the center of the report, the conclusion is the most reassuring one possible in coagulation medicine: the frightening numbers on the laboratory report were never a threat to life.

Congenital afibrinogenemia is an autosomal recessive disorder affecting roughly one in one million people worldwide. It results from pathogenic variants in the genes encoding the fibrinogen protein chain, most commonly the FGA, FGB, or FGG genes, and is defined by the complete or near-complete absence of circulating fibrinogen. Because fibrinogen is the precursor of fibrin—the polymerized protein mesh that stabilizes platelet plugs and forms the scaffold of mature clots—its absence has classically been associated with bleeding. Patients with the condition suffer from everything from umbilical stump hemorrhage in infancy to spontaneous muscle, joint, and intracranial bleeds throughout life. Fibrinogen also serves as a critical bridge for platelet aggregation, binding to the platelet glycoprotein IIb/IIIa receptor to link platelets to one another. Remove fibrinogen entirely, the textbook reasoning goes, and robust clot formation becomes nearly impossible. That reasoning, as this case demonstrates, is incomplete.

The patient presented with laboratory results that, to any clinician unfamiliar with the disorder’s paradoxes, would suggest a state of profound anticoagulation rather than one of active thrombosis. His prothrombin time, partial thromboplastin time, and thrombin time all exceeded 200 seconds, with reference ranges of under 15, under 38, and under 17 seconds respectively. His international normalized ratio exceeded 16. Both fibrinogen activity, measured by the Clauss method, and fibrinogen antigen were below the level of quantification. Most strikingly, his D-dimer—the fibrin degradation product used around the world as a screening tool for venous thromboembolism—was low, measuring under 215 ng/mL against a reference ceiling of 500 ng/mL. Yet venous duplex ultrasound revealed an extensive acute occlusive deep vein thrombosis extending from the left peroneal vein all the way to the femoral profunda vein.

The explanation for this contradiction lies in the biology of the assays themselves. D-dimer is generated when plasmin cleaves cross-linked fibrin. If there is no fibrinogen to form fibrin in the first place, there can be no cross-linked fibrin to degrade, and therefore no D-dimer released into the circulation, regardless of how much thrombotic activity is actually occurring within the vessels. The clotting times tell a similar story: PT, PTT, and thrombin time all depend on the conversion of fibrinogen to fibrin as a terminal readout, so when fibrinogen is absent, these assays are uniformly and maximally prolonged, bearing no relationship to a patient’s actual thrombotic risk. The authors of the report emphasize that in afibrinogenemia, the entire battery of fibrin-dependent laboratory tests becomes functionally blind. Diagnosis of venous thromboembolism in such patients must rest on clinical suspicion and imaging alone.

Why a person without the principal clotting scaffold develops clots at all remains only partly understood, but several mechanisms have been proposed. Chief among them is the notion of unopposed thrombin. In normal hemostasis, thrombin generated at the site of injury is progressively sequestered and neutralized by binding to fibrin, which absorbs the enzyme into the clot structure. In the absence of fibrin, free thrombin persists in the circulation, free to activate platelets, catalyze downstream coagulation cascades, and promote thrombus growth through fibrin-independent pathways. Impaired fibrinolysis compounds the problem, since the fibrinolytic system that normally remodels and dissolves clots loses its principal substrate and regulatory anchor. Von Willebrand factor-mediated platelet activation may also contribute independently of fibrin. A review of 128 patients with inherited fibrinogen disorders cited in the report found that thrombotic events occurred frequently, both spontaneously and in association with triggers such as trauma, surgery, and pregnancy, confirming that the risk is clinically meaningful and multifactorial rather than a curiosity of case reports.

In this patient, the trigger appears to have been a soccer match—an episode of minor tissue injury and relative immobilization sufficient, in a susceptible individual, to tip the hemostatic balance toward thrombosis. His childhood history included a diagnosis of congenital afibrinogenemia with prior bleeding episodes treated with fibrinogen replacement, which made the therapeutic challenge all the more acute. Treatment began with enoxaparin, a low molecular weight heparin administered at 1 mg/kg twice daily, chosen for its predictable pharmacokinetics and reversibility. Anti-Xa monitoring was not performed given standard weight-based dosing and the absence of renal impairment. Two days later he was transitioned to apixaban, a direct oral factor Xa inhibitor, at 5 mg twice daily—primarily because of the patient’s religious restriction regarding porcine-derived products, which made continued heparin therapy impractical, and because apixaban allowed feasible outpatient management. The authors acknowledge that evidence for direct oral anticoagulants in afibrinogenemia is limited, but argue for their cautious practicality in carefully selected patients.

Alongside anticoagulation came the equally delicate task of fibrinogen replacement, which risks pouring fuel on the thrombotic fire if overdone, yet must provide enough hemostatic reserve to prevent bleeding in a therapeutically anticoagulated patient. The team initially targeted fibrinogen activity of at least 50 mg/dL, using human fibrinogen concentrate (RiaSTAP) at a starting dose of one vial of 1026 mg. When fibrinogen levels remained persistently undetectable, the dose was escalated to two vials, approximately 2052 mg or 29 mg/kg, and the target was raised to above 100 mg/dL to provide a more reliable reserve given the concurrent anticoagulation. Subsequent dosing was adjusted according to serial measurements, with trough levels checked before infusions and peak levels approximately one hour after, typically administered every two to three days. D-dimer was deliberately not trended after replacement began, given the known limitations of the assay in this condition. The patient remained hospitalized for 14 days, during which his pain decreased, his limb swelling improved, and his ambulation recovered, all without any bleeding complications.

Follow-up genetic testing confirmed the reported diagnosis at the molecular level. The patient was found to be homozygous for a pathogenic variant in the FGB gene, c.862G>A, classified as likely pathogenic. This variant has a reported allele frequency of only 0.0026% among individuals of European non-Finnish descent in the gnomAD database, and has previously been described in the homozygous state in individuals with afibrinogenemia and in the heterozygous state in a person with hypofibrinogenemia. The authors note that genetic testing plays a crucial role in confirming and classifying quantitative fibrinogen disorders, particularly when activity and antigen levels are undetectable, and that it informs inheritance patterns essential for counseling, especially in consanguineous families. However, the variant has not been consistently associated with increased thrombotic risk, and genotype–phenotype correlations in these disorders remain poorly defined—leaving clinicians without a genetic roadmap for predicting who among these rare patients might clot.

The patient completed three months of therapy with apixaban twice daily and fibrinogen replacement using Fibryga three times weekly, with interval fibrinogen monitoring. At the end of treatment, his symptoms had resolved and repeat ultrasound showed only chronic, non-occlusive thrombotic changes—a residual scar of the episode rather than an active threat. Long-term fibrinogen prophylaxis was deliberately not initiated, a decision reflecting the need to balance his history against future thrombotic risk: with no recurrent bleeding, routine replacement might paradoxically expose him to further clots. He finished the treatment course with no major adverse events, an outcome the authors present as anecdotal support for the cautious combined approach they adopted.

The broader lessons of the case extend well beyond a single rare disease. For clinicians, the report is a warning that D-dimer, one of the most widely deployed screening tests in medicine, can fail catastrophically in patients with quantitative fibrinogen disorders, and that normal clotting screens in such patients say nothing about thrombotic danger. When afibrinogenemia is known or suspected and a patient presents with limb swelling, pain, or other features of venous thromboembolism, imaging must take precedence over laboratory screening. For researchers, the case highlights the absence of standardized regimens for fibrinogen replacement in the setting of concurrent anticoagulation, and the need for prospective studies to define thrombotic risk and develop evidence-based management strategies for this population. Nearly a century after congenital afibrinogenemia was first described in 1920, the disorder continues to challenge the assumption that bleeding and clotting occupy opposite ends of a single dial—and to show that in hemostasis, as in much of biology, the absence of a system does not mean the absence of surprises.